Health Canada issued a Notice of Compliance with Conditions for Imbruvica (ibrutinib) an oral, once-daily single-agent therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma.
LEHIGH VALLEY HEALTH NETWORK announced it will join the Memorial Sloan Kettering Cancer Alliance.
Teva Parenteral Medicines Recalls Adrucil The FDA published a draft guidance for the pharmaceutical industry to ensure that FDA-regulated medications are continually manufactured under strict quality standards.
Carolyn Mary Kaelin, a surgical oncologist in the Women's Cancers Program at Dana-Farber and director of the Breast Clinic at Brigham and Women's Hospital, died July 28, surrounded by loved ones. Kaelin was 54.
Medicare's Part D program paid significantly higher prices for drugs than either Medicaid or the Veterans Health Administration, a study by Carleton University and Public Citizen found.
After a decade of near-absence from the US market, the AstraZeneca drug Iressa (gefitinib) is back.
Peter Schulam, professor of urology and chief of Yale’s Department of Urology, will serve as the interim director of Yale Cancer Center and physician-in-chief at Smilow. Lynch joined Yale Cancer Center as director in 2009 and assumed the role of inaugural physician-in-chief at Smilow, which opened that year. During his tenure, more than 130 scientists […]
THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT and the Ontario Institute for Cancer Research announced a call for pre-proposals from Canadian academic investigators focused on early-stage technologies.
TIMOTHY LASH was named leader of the Cancer Prevention and Control Research Program at Winship Cancer Institute of Emory University.
KAREN RECKAMP was named medical director for clinical research operations at City of Hope.
